Ultragenyx Pharmaceutical.
biopharmaceutical company based in Novato, California, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 67
What's happening
Earlier this month
One to three months ago
-
The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.Well supported5 reports
-
Ultragenyx Pharmaceutical and Immunome, Inc. are being compared on various financial metrics, including share price volatility against the S&P 500.Some support1 report
-
Ultragenyx Pharmaceutical and Disc Medicine, Inc. are both mid-cap healthcare companies currently under review.Some support1 report
Gone quiet
No new reports in 90+ days-
Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.Some support9 reports
-
Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.Some support2 reports1 development inside
-
Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.Some support3 reports2 developments inside
-
Ultragenyx Pharmaceutical must file required documents regarding its NASDAQ company status with the SEC.Some support1 report
-
Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.Some support1 report
-
Ultragenyx Pharmaceutical reported a grant under Nasdaq listing rules on June 21, 2025.Speculative1 report
-
The FDA rejected the biologics license application submitted by Ultragenyx Pharmaceutical.Some support3 reports
-
The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.Some support2 reports
-
Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.Some support1 report
-
The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.Some support1 report
-
William Blair maintained a bullish Buy stance on Ultragenyx Pharmaceutical on July 16, 2025.Some support1 report
-
FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.Some support2 reports
-
Crysvita, a product of Ultragenyx Pharmaceutical, received breakthrough therapy designation for its drug GTX-102, while also generating revenue in Turkey and Europe.Well supported7 reports
-
Ultragenyx Pharmaceutical submitted a Rolling BLA for its DTX401 gene therapy to the FDA.Some support2 reports
-
Eric Crombez, who serves as Chief Medical Officer, was involved in a conference in London with Ultragenyx Pharmaceutical.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Ultragenyx Pharmaceutical this week
News at the entities that move Ultragenyx Pharmaceutical most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Ultragenyx Pharmaceutical
-
Citigroup TransactionalMorgan Stanley and Citigroup cut AutoNation's rating and price objective on November 6, 2026.Moves Ultragenyx Pharmaceutical
-
Cantor Fitzgerald TransactionalCantor Fitzgerald raised its target price for Apple Hospitality REIT (APLE) on June 18th.Moves Ultragenyx Pharmaceutical
-
representative TransactionalLocal activists are pressuring an elected representative to abolish ICE following the proposal of a detention center in Tri-Valley.Moves Ultragenyx Pharmaceutical
-
Jefferies Financial Group StructuralAlabama retirement systems lowered their position while Amundi increased its stake and Jefferies issued a hold rating.Moves Ultragenyx Pharmaceutical
-
Royal Bank of Canada TransactionalMorgan Stanley began coverage of Vylor with an 'overweight' rating, while Royal Bank of Canada authorized a $3.00 billion stock buyback plan.Moves Ultragenyx Pharmaceutical
Connections
The 21 strongest of 67, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Emil Kakkis Structural
Emil Kakkis is the founder and chief executive officer of Ultragenyx Pharmaceutical.
-
Citigroup Transactional
Citigroup raised its target price for Ultragenyx Pharmaceutical from $31.00 to $32.00, accompanied by a buy rating.
-
representative Transactional
Representative purchased shares of Ultragenyx Pharmaceutical.
-
FDA Structural
The FDA formally regulates Ultragenyx Pharmaceutical through drug approval processes, designations, and complete response letters.
-
Cantor Fitzgerald Transactional
Cantor Fitzgerald issues analyst reports and sets price targets for Ultragenyx Pharmaceutical.
-
Nasdaq Structural
Ultragenyx Pharmaceutical is a company that conducts its business and trades its stock on the Nasdaq exchange.
-
Jefferies Financial Group Structural
Jefferies provides market ratings and price targets for Ultragenyx stock.
-
Royal Bank of Canada Transactional
Royal Bank of Canada issued a stock downgrade affecting market valuation of Ultragenyx Pharmaceutical.
Show all 21 connections
-
Eric Crombez Structural
Eric Crombez holds the formal position of Chief Medical Officer at Ultragenyx Pharmaceutical.
-
Morgan Stanley Mentioned together
Morgan Stanley provides investment ratings and price targets for Ultragenyx Pharmaceutical.
-
ORBIT Structural
Ultragenyx's drug development progress depends on receiving study results from Orbit.
-
William P. Blair Mentioned together
William Blair, through its research firm, issued stock ratings for Ultragenyx Pharmaceutical, culminating in a downgrade.
-
Securities and Exchange Commission Structural
Ultragenyx Pharmaceutical must comply with SEC filing requirements for its company status.
-
Turkey Shared context
Ultragenyx Pharmaceutical operates and generates revenue from its drug Crysvita within the market of Turkey.
-
MarketBeat Mentioned together
MarketBeat publishes financial data, including average ratings and consensus price targets, for Ultragenyx Pharmaceutical.
-
TD Cowen Mentioned together
TD Cowen provides financial research coverage on Ultragenyx Pharmaceutical.
-
North America Shared context
The company operates and generates revenue within the North American market region.
-
Benzinga Mentioned together
Benzinga reports on company stock performance, including Ultragenyx Pharmaceutical's market activity.
-
Latin America Shared context
Ultragenyx Pharmaceutical is expanding its market presence within the Latin American region.
-
Revvity Mentioned together
Both Revvity and Ultragenyx Pharmaceutical are identified as publicly traded biopharma companies.
-
Novato Shared context
Ultragenyx Pharmaceutical is based in Novato, California.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
15 events- Ultragenyx Pharmaceutical and BioHarvest Sciences Inc. are companies operating in the Medical - Biomedical and Genetics industry.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.
- Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.
- Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.
- Ultragenyx Pharmaceutical reported a grant under Nasdaq listing rules on June 21, 2025.
- The FDA rejected the biologics license application submitted by Ultragenyx Pharmaceutical.
- The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.
- Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.
- The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
- William Blair maintained a bullish Buy stance on Ultragenyx Pharmaceutical on July 16, 2025.
- FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
- Crysvita, a product of Ultragenyx Pharmaceutical, received breakthrough therapy designation for its drug GTX-102, while also generating revenue in Turkey and Europe.
- Ultragenyx Pharmaceutical submitted a Rolling BLA for its DTX401 gene therapy to the FDA.
- Eric Crombez, who serves as Chief Medical Officer, was involved in a conference in London with Ultragenyx Pharmaceutical.